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A B S T R A C T
Speciﬁc soluble biomarkers can be powerful tools for the diagnosis, prognosis and personalized
management of osteoarthritis (OA). Biomarkers are potential indicators of the effect of a drug on
cartilage metabolism and provide crucial information about the mechanisms of drug action. In this
review, we address key questions concerning the use of biomarkers in OA management: Why do we need
soluble biomarkers? What are the most widely investigated biomarkers derived from cartilage
extracellular matrix? What are the most common pitfalls in interpreting soluble biomarker
measurements? What are the perspectives and future research directions in this ﬁeld? We review
current evidence to propose that cartilage-derived soluble biomarkers are complementary ‘‘drug
development tools’’ that can be applied during drug development from preclinical research to clinical
evaluation. In the future, such biomarkers could be surrogate markers of clinical and/or imaging
outcomes. Successful standardization and implementation of automated biomarker assays will facilitate
their use in companion diagnostics in the context of personalized medicine for enhanced management of
OA.
 2016 Elsevier Masson SAS. All rights reserved.
Available online at
ScienceDirect
www.sciencedirect.com1. Introduction
Osteoarthritis (OA) is one of the major causes of pain and
disability in the adult population. OA is now considered a severe joint
disease affecting all articular tissues (i.e., cartilage, synovial
membrane, meniscus and ligaments) and also periarticular tissues
including tendons, adipose tissue and muscles. These joint tissues
undergo metabolic, structural and functional alterations that
contribute to the initiation and increased chronicity of pain and
synovitis, activating pro-inﬂammatory pathways of innate immuni-
ty, facilitating disease progression and leading to patient disability.
OA is a risk factor for some other age-related co-morbidities such as* Corresponding author at: Bone and cartilage Research Unit, Arthropoˆle Lie`ge,
Institute of Pathology, level +5, CHU Sart-Tilman, 4000 Lie`ge, Belgium.
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1877-0657/ 2016 Elsevier Masson SAS. All rights reserved.diabetes or cardiovascular diseases [1,2]. Therefore, OA must be
better managed to prevent these co-morbidities.
Pain is a key determinant of kinesiophobia in OA patients; it is
responsible for physical deconditioning and a sedentary lifestyle,
which is probably a decisive factor in the association of OA and
metabolic syndrome, obesity and cardiovascular disorders [3].
Low-grade chronic systemic inﬂammation is the link between
articular and periarticular tissues via pro-inﬂammatory mediators.
This low-grade systemic inﬂammation may result from physiolog-
ical aging (inﬂammaging) or metabolic disorders (meta-inﬂam-
mation) [4,5] (Fig. 1).
The challenge for the next decade will be to ﬁnd better remedies
and management strategies for OA and to identify tools that can
help in diagnosis and monitoring disease progression as well as
assessing the efﬁcacy of new therapeutic interventions. These tools
need to be accurate for monitoring the structural progression of
the disease and sensitive enough to identify early events at the
molecular level and objectively assess the efﬁcacy of novel or
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Fig. 1. Global representation of the systemic contributors and co-morbid situations associated with the pathogenesis of osteoarthritis (OA).
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these tools. This review addresses the following key questions
concerning the use of biomarkers in OA management.
2. How to deﬁne and classify OA biomarkers?
The National Institutes of Health (NIH) Biomarkers Deﬁnitions
Working Group deﬁned a biomarker as ‘‘a characteristic that is
objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention’’ [6]. Existing biomarkers
can be categorized by the OA process targeted, as markers of
cartilage degradation/synthesis, bone remodeling, or synovitis. They
can also be classiﬁed as ‘‘dry’’ or ‘‘wet’’ biomarkers. ‘‘Dry’’ biomarkers
may include imaging features, visual analog scales or questionnaires
and ‘‘wet’’ biomarkers may include proteins, protein fragments,
metabolites or microRNAs. The BIPEDS system classiﬁes the major
types of biomarkers according to their clinical background into
6 categories corresponding to burden of disease, investigational,
prognostic, efﬁcacy of intervention, diagnostic and safety [6]. The
adoption and use of this classiﬁcation system has been encouraged
to communicate advances within a common framework and so that
OA biochemical marker research is more transparent and efﬁcient,
offering suggestions on optimal study design and the development
of analytical methods for use in OA-focused investigations. In 2011,
the Osteoarthritis Research Society International/Food and Drug
Administration (OARSI/FDA) Biomarkers Working Group classiﬁed
biomarkers into 4 categories (exploration, demonstration, charac-
terization and surrogacy levels) by their level of qualiﬁcation for
drug development [7]. More recently, the OARSI RCT working group
published guidelines for soluble biomarker assessment in OA clinical
trials [8]. This document summarizes the use of biomarkers at
5 stages, including preclinical development and phase I to IV trials.
3. Why do we need soluble biomarkers in OA?
The management of OA often begins too late during the course
of the disease. It is generally initiated after the patient complaints
about joint pain and loss of function, which is conﬁrmed by the
presence of radiographic changes [9]. Unfortunately, by the time
the disease is diagnosed radiographically, joint tissue degenerationis already well established and in most cases irreversible. Clinical
OA is now considered to be preceded by a ‘‘silent’’ pre-radiographic
phase during which extensive metabolic changes occur in joint
tissues, without any pain. One challenge is the detection of these
early metabolic changes that are early indicators of abnormal joint
changes before the occurrence of structural changes.
OA is a heterogeneous syndrome with different clinical pheno-
types deﬁned by risk factors, progression proﬁles, co-morbidities,
signs and symptoms. Although one goal is to have clearly deﬁned and
demarcated OA phenotypes, the classiﬁcation and identiﬁcation of
phenotypes of OA is difﬁcult in clinical studies or in clinical practice
because of all these factors. Thus, we need a better subgrouping of
OA, especially when several processes may overlap and various
tissues are dominant during different phases of the disease. In real
life, different OA phenotypes likely overlap signiﬁcantly and thus are
difﬁcult to be separated into distinct clusters. However, establishing
better-deﬁned biological proﬁles speciﬁc to each phenotype may
help in clustering the phenotypes.
Another key concern in OA management is the absence of
effective treatment or cure. We lack standard treatments that allow
for objective assessment of the sensitivity of a biomarker to a
particular intervention and innovative treatments that efﬁciently
address symptoms and disease progression. The reasons for the lack
of effective treatments are the lengthy follow-ups and large sample
sizes required for phases II and III clinical trials. We need sensitive
and reproducible variables to accelerate drug development and
reduce costs and attrition in the pharmaceutical pipelines. Soluble
biomarkers could be considered ‘‘drug development tools’’ accom-
panying drugs from screening to post-marketing phases [9].
Many scientists and clinicians believe that soluble biomarkers
could be helpful tools for addressing all these concerns. However, the
development of a biomarker is a lengthy process requiring robust
and reproducible assays that pass independent validation tests as
well as the clinical characterization of the biomarker in large cohorts.
4. What are the most commonly investigated biomarkers
derived from cartilage extracellular matrix (ECM)?
The cartilage ECM is a rich source of biomarkers in OA. Collagen
type II is the most abundant protein in cartilage [10]. Consequently,
the most popular biomarkers are epitopes located in the collagen II
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II, Coll2-1, C2C and C2M and those representing collagen II synthesis
are PIIANP, PIIBNP and CPII [11]. Other cartilage ECM-derived
markers include cartilage oligomeric matrix protein (COMP) [12],
Coll2-1NO2 [13], CS846 [14], aggrecan epitopes (ARGS, TEGE, FFGV)
[15] and ﬁbulin-3 epitopes (Fib3-1, Fib3-2, Fib3-3) [16]. COMP is a
noncollagenous ECM protein formed of 5 identical glycoprotein
subunits, each with epidermal growth factor-like and calcium-
binding (thrombospondin-like) domains. COMP is a marker of
cartilage ECM turnover [12]. Coll2-1NO2 is the nitrated form of
Coll2-1 reﬂecting the oxidative-related cartilage ECM degradation
[13]. CS846 is an epitope located in the chondroitin sulfate chain of
aggrecan and an indicator of large or fetal-like aggrecan synthesis
[14]. In contrast, TEGE/ARGS and FFGV are derived from degradation
by aggrecanases and matrix metalloproteinases (MMPs). Originally
discovered by proteomics to be increased in urine from OA patients
[16], the ﬁbulin-3 epitopes (Fib3-1, -2 and -3) contain a speciﬁc
sequence of ﬁbulin-3 (Fib3), an extracellular glycoprotein widely
distributed in various connective tissues including blood vessels,
bone, ligament and cartilage. Fib3 inhibits angiogenesis and chon-
drocyte differentiation [17]. More precisely, its overexpression
suppresses chondrocyte differentiation by inhibiting cartilage node
formation, proteoglycan production and aggrecan gene expression.
Furthermore, its overexpression selectively maintains the expres-
sion of Sox-9 but suppresses that of Sox-5 and -6. Fib3 also interacts
with tissue inhibitor of metalloproteinase 3, a matrix-bound
inhibitor of MMPs [18]. Fib-3 is cleaved by MMP-1, -2, -3, -7, -9
and -12 [19] (Fig. 2).
5. What are the common pitfalls in the interpretation of
biomarker measurements?
There are several limitations in interpreting the results of
biomarker assays. A recent review published in the ofﬁcial journal
of the OARSI summarizes the best practice for clinical trials using
biomarkers [8]. Some limitations are related to the assay itself and
type of assay, and others related to environmental conditions such
as food intake, physical activity and circadian rhythms can be
critical factors. All these conditions must be veriﬁed before the use
of an assay in clinical study. The techniques should be reproducible
and internationally validated by several independent laboratories
like replication in genetics; the coefﬁcient of variations of the assay
should at best not exceed 10%; and analysis of the value should
involve controlling for several confounding factors such as age, sex,
body mass index and bone status for markers of bone turnover.Fig. 2. An overview of cartilage-Another important point is the speciﬁcity of the biomarker. To
monitor the progression of OA or predict its incidence or progression
in the general population, we need biomarkers that are speciﬁc and
not confounded by systemic inﬂammatory diseases. For example, a
biomarker reﬂecting bone metabolism could be more predictive of
osteoporosis rather than OA. Indeed, many biomarkers are shared by
subchondral bone and articular cartilage and can be useful for
osteoporosis and OA. As well, the conformation of the biomarker in
the biological ﬂuid must be determined. Most assays detect an
epitope or a neo-epitope, and for assays, antibodies are produced by
injecting synthetic peptides. The form of this type of epitope in
blood, urine or synovial ﬂuid is not known. The epitope may be part
of a protein fragment or present within several fragments of
differing molecular weights.
In addition, the presence of severe kidney or liver disease may
induce a bias in interpreting a biomarker value. The diseases may
strongly modulate the renal clearance of biomarkers indepen-
dent of the joint disease activity. This point has never been
adequately addressed and must be considered in the design of
clinical trials.
Another important point to consider in the prognostic value of a
biomarker is the dynamic variations in serum levels over time. A
study by Sharif et al. [20] showed that serum level of COMP is
dynamic and more reﬂective of upcoming variations in joint space
narrowing than the long-term evolution of disease over a period of
years. However, the problem might be complicated by the
nonlinear relationship between biomarkers and some structural
variables. A biomarker may reﬂect a metabolic change that is not
necessarily related to structural or clinical changes. Hence, one
may question the relevance of qualifying a biomarker by its
relationship with clinical and radiological criteria. A soluble
biomarker is primarily used to investigate changes in tissue or
organ metabolism instead of a structural change that may result
from a one-time traumatic event.
The ﬁnal issue that needs to be considered is joint speciﬁcity.
Some biomarkers have a diagnostic or a prognostic value for knee
or hip OA compared to healthy subjects, despite the presence of
overlap between groups, so deﬁning a cutoff value is difﬁcult.
Biomarkers are often qualiﬁed by using cohorts with one
particular OA phenotype. Few biomarkers have been validated
in the general population that is representative of the most
common phenotypes and rarely (if ever) investigated in a well-
stratiﬁed cohort. For example, a biomarker could predict the
progression of an aging phenotype but not an obese/overweight
phenotype.derived soluble biomarkers.
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The ‘‘omics’’ approach is a general exploratory approach that be
used to investigate alterations in a large number of genes, transcripts,
proteins, lipids and metabolites in healthy versus diseased tissues.
The challenge with such an approach is to differentiate candidates
that are speciﬁcally involved in the disease process. The most
commonly used omics approaches include genomics (beyond the
scope of this review), proteomics, lipidomics, metabolomics and
transcriptomics. Omics technologies applied to serum or urine have
revealed numerous new biomarkers that are ubiquitous molecules in
most cases [21]. A promising research pathway is the development
and reﬁnement of omics technologies for speciﬁc application to joint
tissues (cartilage, bone, meniscus, synovial membrane) and the
comparison of omics proﬁles of tissues at different stages of the
evolution of the disease. This approach would provide a range of
biomarkers reﬂecting the metabolic changes in different articular
tissues at different disease stages. However, we need to remember
that validation, qualiﬁcation, industrialization and production of an
assay are long, arduous and costly processes. Therefore, we must
select the most promising of these omics candidates with predeﬁned
criteria such as tissue or pathological pathway speciﬁcity.
A most promising approach is the multiplexing of biomarkers
investigating different tissue metabolisms or pathological path-
ways. A sensitive multiplex assay could combine several biomarkers,
for example, for collagen II synthesis (i.e., PIIANP) and degradation
(i.e., Coll2-1 or CTX-II), bone remodelling (i.e., PINP) and synovitis
(i.e., HA). Data from multiplex platforms could be integrated in
aggregate scores combining imaging, clinical and biological markers.
This combination approach is an important step toward personal-
ized medicine.
7. Conclusions
Soluble cartilage ECM-derived biomarkers can be used for
clinical and imaging outcomes and as objective tools for evaluating
responses to speciﬁc treatments in clinical trials of OA. Metabolic
changes in joint tissues may occur early in OA development, long
before the appearance of symptoms and structural changes, and
should be considered a therapeutic variable. We have many
soluble biomarkers derived from cartilage ECM that can be used as
good ‘‘drug development tools.’’ A wide panel of biomarkers should
be tested in the preclinical phase of development to better
understand mechanisms of drug action and to identify companion
marker(s) for subsequent clinical phases. This approach should
reduce the length and cost of drug development. In the near future,
some biomarkers might qualify as markers of efﬁcacy of treatment
and be used in routine follow-up of personalised therapeutic
interventions. This situation will require a long-term qualiﬁcation
phase for a particular phenotype or a large panel of OA patients
representative of the global population. The routine use of OA
biomarkers also requires a successful commercialisation and
production of assay techniques. Of note, this target is one of the
most challenging for the upcoming years. It may affect the daily
practice of primary care physicians and also the economic aspects
of disease management by reducing the cost burden of the disease
in targeting responders for particular treatments.
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